Skip to main content
    C

    Cardiol Therapeutics Inc Class A (CRDL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.98
    -0.02 (-2.02%)

    Market Cap: $127.69M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cardiol Therapeutics Inc Class A (CRDL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in CAD.

    Cardiol Therapeutics Inc Class A reported revenue of CAD 0 for the fiscal year ended Dec 31, 2025. That year, net income was CAD -33.82M, operating cash flow was CAD -23.85M and free cash flow was CAD -23.88M. The quarter ended Sep 30, 2026 had net income of CAD -12.98M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of CAD 34.32M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 20250N/AN/AN/AN/A
    Dec 20240N/AN/AN/AN/A
    Dec 20230N/AN/AN/AN/A
    Dec 20220-100.0%N/AN/AN/A
    Dec 202162.27K-20.9%-179.9%-49092.4%-40170.9%
    Dec 202078.76KN/A-228.8%-20620.3%-20570.9%
    Dec 20190N/AN/AN/AN/A
    Dec 20180N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue000062.27K78.76K00N/A
    Cost of revenueN/AN/A187.38K162.23K174.26K180.17K116.11K91.49K53.34K
    Gross profitN/AN/A-187.38K-162.23K-112.00K-180.17K-116.11K-91.49K-53.34K
    Research and development14.02M14.01M10.73M13.99M8.59M8.25M2.72M1.53M441.26K
    Operating income-34.32M-40.28M-22.47M-30.49M-30.57M-16.24M-10.89M-7.39M-1.59M
    Net income-33.82M-36.68M-21.22M-22.82M-25.01M-16.20M-10.55M-15.89M-1.66M
    EBITDA-33.72M-36.30M-20.97M-22.60M-24.79M-15.97M-10.40M-7.30M-1.50M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit-12.45KN/A-26.78K-25.95KN/AN/AN/A-33.70KN/A-45.24K-61.62KN/A
    Operating income-9.55M-11.28M-9.73M-8.03M-10.18M-7.68M-8.43M-6.94M-14.14M-5.66M-8.41M-8.03M
    Net income-12.98M-8.64M-10.85M-7.21M-9.96M-8.35M-8.29M-5.68M-12.73M-4.82M-9.18M-7.64M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of CAD 38.35K by 21.38M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets23.62M31.86M36.70M45.76M87.88M15.89M15.50M24.68M3.22M
    Current assets23.50M31.67M36.15M45.32M87.14M14.95M14.37M24.03M2.48M
    Cash and equivalents21.42M30.58M34.93M43.83M83.90M14.03M6.96M16.73M2.36M
    Total liabilities5.74M7.14M8.45M7.25M11.64M2.62M830.83K2.41M366.76K
    Short-term debt38.35K33.01K15.81K37.21K44.71K51.91K50.47KN/AN/A
    Long-term debtN/AN/AN/AN/AN/AN/AN/A269.22K190.04K
    Shareholder equity17.88M24.73M28.25M38.51M76.24M13.27M14.67M22.27M2.85M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets33.00M29.37M31.49M23.62M12.95M19.94M25.45M31.86M17.52M26.31M31.13M36.70M
    Total liabilities5.30M5.33M7.22M5.74M3.39M8.13M7.87M7.14M7.09M10.95M11.07M8.45M
    Cash and equivalents29.33M26.09M27.74M21.42M11.62M18.20M23.29M30.58M15.89M24.02M28.57M34.93M
    Shareholder equity27.70M24.04M24.27M17.88M9.56M11.81M17.59M24.73M10.43M15.36M20.06M28.25M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-23.85M-25.06M-25.18M-27.22M-23.55M-9.13M-11.38M-10.89M-1.29M
    Capital expenditures24.48K21.29K64.31K74.71K12.92K40.60K424.31K13.79K29.17K
    Free cash flow-23.88M-25.08M-25.24M-27.30M-23.56M-9.17M-11.80M-10.91M-1.32M
    Investing cash flow-24.48K-21.29K-64.31K-74.71K-12.92K-40.60K-424.31K-13.79K-29.17K
    Financing cash flow15.54M18.84M-55.38K-53.93K93.44M16.30M2.03M25.28M3.68M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-4.46M-4.38M-7.54M-5.23M-6.93M-4.55M-7.15M-5.59M-7.77M-4.78M-6.92M-6.46M
    Capital expenditures23.97K3.03K47.71K3.09K3.02K6.44K11.94K6.16K7.87K3.80K3.46K10.71K
    Free cash flow-4.48M-4.38M-7.58M-5.23M-6.93M-4.56M-7.17M-5.60M-7.78M-4.78M-6.93M-6.48M
    Last 12 quarters

    Frequently Asked Questions About CRDL

    What is Cardiol Therapeutics Inc Class A's annual revenue?

    Cardiol Therapeutics Inc Class A reported revenue of CAD 0 for the fiscal year ended Dec 31, 2025.

    Is Cardiol Therapeutics Inc Class A profitable?

    No. Cardiol Therapeutics Inc Class A reported net income of CAD -33.82M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CRDL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of CAD -23.85M minus capital expenditures of CAD 24.48K produced free cash flow of CAD -23.88M.

    How much debt does Cardiol Therapeutics Inc Class A have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of CAD 38.35K and cash and equivalents of CAD 21.42M.